USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Boston, USA-based biotech Aktis Oncology, which is targeting alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. 1 October 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
Italian biotech Genespire—which is developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases—has announced the closing of a 46.6 million euros ($52 million) Series B financing. 25 September 2024
Healthcare plan provider Centivo has raised $75 million in equity and debt financing to support its goal of offering affordable care to employees and their families. 25 September 2024
Rare disease firm bluebird bio has announced a company-wide restructuring aimed at cutting costs by 20% and achieving quarterly cash flow break-even by the second half of 2025. 25 September 2024
Aptadir Therapeutics, a biotech company focused on RNA inhibitor-based therapies for cancer and genetic conditions, has launched with $1.6 million in pre-seed funding. 24 September 2024
Australian biotech company Telix Pharmaceuticals is to acquire USA-based RLS Radiopharmacies, expanding its manufacturing and distribution footprint in North America. 24 September 2024
British biotech Vicebio has secured $100 million in a series B funding round to accelerate the development of its next-generation vaccines against respiratory viruses. 23 September 2024
USA-based Be Biopharma (“Be Bio”), a pioneer in the discovery and development of Engineered B Cell Medicines (BeCM) founded in October 2020, has announced the closing of a $130 million financing, bringing the total investment in the company to over $180 million. 14 April 2022
Biotech funder and incubator Flagship Pioneering today announced that Michael Severino is joining the company as chief executive (CEO)-partner. 13 April 2022
Anglo-Irish firm Poolbeg Pharma has announced that a number of new investors have expressed interest in acquiring up to £1.6 million ($2.1 million) in shares of the company which are currently locked-up and held in trust by Croft Nominees as a result of the distribution in specie from Open Orphan. 13 April 2022
Global investment firm Carlyle announced today that it has agreed to acquire Abingworth, a transatlantic life sciences investment firm with over $2 billion in assets under management (AUM), to bolster Carlyle’s leading global healthcare franchise and enter the biotech financing arena. 11 April 2022
Tetraneuron, a Spanish biotech taking a multifactorial approach to Alzheimer's through gene therapy, is to start a new round of financing. 6 April 2022
Adding to a growing list of major investments in AI-based life sciences companies, $150 million in series C funding has been provided to American start-up ConcertAI. 29 March 2022
In the latest in a series of life sciences SPAC mergers, Ligand Pharmaceuticals is to use the approach to hive off its antibody business. 24 March 2022
LifeMine Therapeutics, a US start-up searching the fungal biosphere for genetically-encoded small molecules (GEMs), has announced the completion of a $175 million Series C financing. 23 March 2022
Nucleai, an Israeli based AI-powered spatial biology company with a mission to transform drug development and clinical treatment decisions by unlocking the power of pathology data, has closed a Series B financing for $33 million. 23 March 2022
US biotech start-up Affini-T Therapeutics today announced the completion of an oversubscribed $175 million financing that was co-led by Vida Ventures and Leaps by Bayer. 22 March 2022
French drugmaker Sanofi has moved forward with the Euronext listing of EUROAPI, which has been billed as the future leading European company dedicated to the development, production and marketing of active pharmaceutical ingredients (API). 18 March 2022
Shares of CNS focussed US pharma firm Impel NeuroPharma were up 5.3% at $6.98 early afternoon, having risen as high as $7.24, after it announced two separate transactions with funds managed by Oaktree Capital Management, totaling $100 million in gross funding. 17 March 2022
Texas, USA-headquartered T-cell therapeutics company Triumvira Immunologics today announced the completion of an extension of its Series A financing, bringing the total round to approximately $100 million. 17 March 2022
Shares of 2seventy bio were up almost 10% at $13.40 this morning, after the US immuno-oncology cell therapy company announced it has agreed to sell around13,934,427 shares of its common stock to a select group of institutional and accredited investors in a private placement. 16 March 2022
French pharma major Sanofi and Blackstone have entered into a strategic, risk-sharing collaboration under which funds managed by Blackstone Life Sciences (BXLS) will contribute up to 300 million euros ($330 million) to accelerate the global pivotal studies and the clinical development program for the subcutaneous formulation and delivery of the anti-CD38 antibody Sarclisa (isatuximab-irfc), to treat patients with multiple myeloma (MM). 15 March 2022
Midway through its annual report, Massachusetts-based gene therapy company bluebird bio (Nasdaq: BLUE) made the startling admission that it’s running out of cash, fast. 7 March 2022
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news